高级检索
当前位置: 首页 > 详情页

The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 自然指数

机构: [1]Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China [2]Department of Rheumatology, the Second Affiliated Hospital of Nanchang University, Nanchang, China [3]Department of Rheumatology, the First Hospital of China Medical University, Shenyang,China [4]Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin, China [5]Department [6]Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [7]Department of Rheumatology, the First People’s Hospital of Yunnan Province, Kunming, China [8]Department of Rheumatology, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China [9]Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China [10]Department of Rheumatology, the First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China [11]Department of Rheumatology, the First Affiliated Hospital of Kunming Medical University, Kunming, China [12]Department of Rheumatology, the First Affiliated Hospital of Baotou Medical College, Baotou, China [13]National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China [14]State Key Laboratory of Common Mechanism Research for Major Diseases, Beijing, China
出处:
ISSN:

摘要:
Idiopathic inflammatory myopathies (IIM) are heterogeneous autoimmune diseases with variable long-term outcomes.To determine the prognosis of IIM.This multicenter, prospective cohort study included Chinese patients with IIM. We calculated the standardized mortality ratios (SMRs) adjusted for age and sex, analyzed causes of death, and identified risk factors for all-cause mortality using a multivariable Cox proportional hazards model.A total of 4,534 patients were included, with 2,902 dermatomyositis, 592 polymyositis, 927 anti-synthetase syndrome (ASS), and 113 immune-mediated necrotizing myositis (IMNM). 510 patients died with a median follow-up time of 46 months. The overall SMR was 6.2 (95% CI 5.7-6.7). Cumulative survival rates at 1, 3 and 10 years were 92.6%, 88.6% and 80.5%, respectively. Leading causes of death included interstitial lung diseases (18.8%), malignancies (18.8%), cardiovascular diseases (CVD, 18.8%), and infections (18.6%), which shifted over time (from ILD/infection to malignancies/CVD). Risk factors for mortality included male, lymphopenia, high serum ferritin, anti-MDA-5, anti-TIF1γ, and anti-Ro 52 antibodies.Underestimation of ASS and IMNM.IIM patients had significantly higher mortality than general population, with variable causes of death and distinct risks based on myositis-specific antibodies. MSAs-based classification may provide deeper insights into pathogenesis and management of IIM.Copyright © 2025. Published by Elsevier Inc.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 皮肤病学
第一作者:
第一作者机构: [1]Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China [14]State Key Laboratory of Common Mechanism Research for Major Diseases, Beijing, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:95910 今日访问量:0 总访问量:836 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号 ICP备案:滇ICP备15003244号